Published in Clin Interv Aging on June 29, 2009
Causes, consequences, and treatment of osteoporosis in men. Drug Des Devel Ther (2013) 0.87
Effects of clodronate combined with hydroxyapatite on multi-directional differentiation of mesenchymal stromal cells. Arch Med Sci (2010) 0.84
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med (2015) 0.75
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 7.09
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 6.88
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc (2008) 5.85
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med (2009) 4.39
Clinical practice. Osteoporosis in men. N Engl J Med (2008) 3.91
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc (2002) 3.09
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab (1996) 2.30
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005) 2.23
Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab (2000) 2.17
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res (2003) 2.15
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab (2004) 2.01
Early discontinuation of treatment for osteoporosis. Am J Med (2003) 2.00
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int (1994) 1.95
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol (2003) 1.92
A model of lifetime osteoporosis impact. Arch Intern Med (1991) 1.91
Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab (1999) 1.86
Bisphosphonates: from bench to bedside. Ann N Y Acad Sci (2006) 1.82
Osteoporosis in men. Endocr Rev (2008) 1.80
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol (1996) 1.70
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol (2008) 1.68
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
Retracted Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med (2005) 1.53
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int (2005) 1.52
Tolerability and compliance with risedronate in clinical practice. Osteoporos Int (2003) 1.51
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44
Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol (2007) 1.43
Osteoporosis in men. Endocr Rev (1995) 1.41
Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol (2008) 1.38
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res (2009) 1.22
Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly--a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int (2005) 1.21
High-intensity resistance training and postmenopausal bone loss: a meta-analysis. Osteoporos Int (2006) 1.17
Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ (1989) 1.17
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab (2006) 1.15
Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int (2003) 1.11
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab (2007) 1.07
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res (2007) 1.05
Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res (2001) 1.04
Severe osteoporosis in men. Ann Intern Med (1995) 1.02
Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res (1997) 1.00
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int (2003) 0.99
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int (2001) 0.96
Endocrine dysfunction in leprosy. Eur J Clin Microbiol Infect Dis (2008) 0.93
Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res (2001) 0.92
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int (2007) 0.91
Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol (2003) 0.91
Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int (2000) 0.89
Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res (2008) 0.87
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res (2002) 0.86
A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res (2002) 0.86
Male osteoporosis: deadly, but ignored. Am J Med Sci (2007) 0.85
A single infusion of zoledronate prevents bone loss after stroke. Stroke (2007) 0.84
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr Rev (2006) 0.79
Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int (2000) 0.79
Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density. J Investig Med (2007) 0.78
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. J Endocrinol Invest (2003) 0.77
Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int J Clin Pract (2007) 0.77
Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging (2003) 0.76
Osteoporosis in male and female leprosy patients. Calcif Tissue Int (1999) 0.76
Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res (2003) 1.73
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol (2006) 1.63
Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos (2011) 1.10
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Efficacy and safety of monthly ibandronate in men with low bone density. Bone (2010) 1.04
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density. J Investig Med (2007) 0.78
The role of 5α-reductase inhibition in men receiving testosterone replacement therapy. JAMA (2012) 0.78
Seasonal iodine deficiency in Latvian school children. Thyroid (2012) 0.77
Risk factors for diminished bone mineral density among male hemodialysis patients--a cross-sectional study. Arch Osteoporos (2012) 0.75